Novo Nordisk A/S cut its cell therapy division, which has been trying to find a cure for type 1 diabetes, as the Ozempic maker continues to slash headcount to focus on lucrative areas of obesity and diabetes treatment. Source: Original Навигация по записям Anduril’s Luckey Wants China Cut Out of US Defense Supply Chain AI’s Growth Leaves Financial Regulators Struggling to Catch Up
